Skip to search formSkip to main contentSkip to account menu

BCX1777

Known as: BCX-1777 
National Institutes of Health

Related topics

Related topics

2 relations
forodesine hydrochloride

Broader (1)

immucillin H

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2008
Review
2008
Novel purine nucleoside analogues for hematological malignancies.
Recently, the search for more effective and safer antineoplastic agents has led to synthesis and introduction into preclinical… 
2006
2006
Forodesine IV (Bcx-1777) Is Clinically Active in Relapsed/Refractory T-Cell Leukemia: Results of a Phase II Study (Interim Report).
Background: Forodesine, a potent, rationally designed purine nucleoside phosphorylase inhibitor, has shown clinical activity in T… 
2006
2006
Oral Forodesine (Bcx-1777) Is Clinically Active in Refractory Cutaneous T-Cell Lymphoma: Results of a Phase I/II Study.
Abstract Background: Forodesine is a potent, rationally designed purine nucleoside phosphorylase (PNP) inhibitor that is orally… 
2004
2004
Intravenous Forodesine (BCX-1777), a Novel Purine Nucleoside Phosphorylase (PNP) Inhibitor, Demonstrates Clinical Activity in Patients with Refractory Cutaneous T-Cell Lymphoma.
The profound suppression of T-cell immunity seen in patients with an inherited PNP deficiency supports the potential application… 
Review
2004
Review
2004
Purine nucleoside phosphorylase inhibitors in T-cell malignancies.
Purine nucleoside phosphorylase (PNP)-deficient children exhibit profound impairment in the T-cell component of their immune… 
2004
2004
Intravenous Forodesine (BCX-1777), a Novel Purine Nucleoside Phosphorylase (PNP) Inhibitor, Demonstrates Clinical Activity in Phase I/II Studies in Patients with B-Cell Acute Lymphoblastic Leukemia.
Forodesine is a potent, specific transition-state analog inhibitor of PNP with clinical activity in T-cell malignancies… 
2004
2004
Antileukemic Activity and Pharmacodynamics of Intravenous Forodesine (BCX-1777), a Novel Purine Nucleoside Phosphorylase (PNP) Inhibitor, in Phase I/II Trials in Patients with Advanced T-Cell…
PNP represents an attractive target for drug development based on the profound, selective impairment of T-cell function seen in… 
2003
2003
Arsenate reduction in human erythrocytes and rats--testing the role of purine nucleoside phosphorylase.
Reduction of the pentavalent arsenate (AsV) to the thiol-reactive arsenite (AsIII) toxifies this environmentally prevalent form… 
2003
2003
Intravenous and oral pharmacokinetic study of BCX-1777, a novel purine nucleoside phosphorylase transition-state inhibitor. In vivo effects on blood 2'-deoxyguanosine in primates.
2002
2002
Comparison of in vivo efficacy of BCX-1777 and cyclosporin in xenogeneic graft-vs.-host disease: the role of dGTP in antiproliferative action of BCX-1777.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)